Cagrilintide: what a phase 2 weight-management trial showed

Evidence discussed: Randomized phase 2 human trial.

What the researchers studied

A multicountry trial studied the amylin analogue cagrilintide in adults with overweight or obesity without diabetes. Over 26 weeks, active groups lost more weight on average than placebo. The design included a liraglutide comparison and assessed tolerability. [1]

How to interpret the result

Gastrointestinal problems, including nausea, were more frequent than with placebo. A dose-finding study does not answer every long-term question. Single-agent results should not be confused with results from a semaglutide combination.

What readers can take from it

The findings support investigation of amylin signaling. They concern the selected participants and trial preparation, without establishing equivalence to research-labelled stock.

This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.

Source

[1] Once-weekly cagrilintide phase 2 trial (2021). PMID: 34798060. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.